Quarterly ResultJul 15, 2026, 06:12 AM
Elevance Health Q2 Operating Revenue $49.8B; Raises FY Adj. EPS to $27.00
AI Summary
Elevance Health reported second-quarter 2026 results ahead of expectations, with operating revenue of $49.8 billion, an increase of 0.8% year-over-year. The company achieved diluted EPS of $6.71 and adjusted diluted EPS of $7.45. Reflecting strong performance, Elevance Health raised its full-year 2026 diluted EPS guidance to at least $20.10 and adjusted diluted EPS guidance to at least $27.00. Additionally, the company increased its FY 2026 operating cash flow guidance to at least $6.0 billion and is accelerating targeted investments.
Key Highlights
- FY 2026 adjusted diluted EPS guidance raised to at least $27.00.
- FY 2026 operating cash flow guidance raised to at least $6.0 billion.
- Q2 2026 operating revenue was $49.8 billion, up 0.8% from Q2 2025.
- Q2 2026 adjusted diluted EPS was $7.45.
- Health Benefits operating revenue was $42.7 billion, up 3% YoY.
- Carelon operating revenue was $19.2 billion, up 6% YoY.
- Repurchased 0.7 million shares for $234 million in Q2 2026.
- Declared Q3 2026 dividend of $1.72 per share.
Price Impact
More from ELV